Ekstrameda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 11,548 | 126,022 | 561,251 | 1,125,477 | 1,099,028 | 1,999,192 | 1,352,788 | 2,065,292 |
| Profit before tax | - | - | - | 494,755 | 371,540 | 1,330,126 | 727,805 | 685,196 |
| Net profit | -12,017 | 7,573 | 366,702 | 419,204 | 312,598 | 1,130,375 | 618,271 | 575,210 |
| Equity | -47,182 | -39,609 | 327,092 | 269,826 | 405,954 | 1,136,329 | 1,154,600 | 965,104 |
| Liabilities | 71,292 | 57,384 | 149,681 | 142,629 | 103,337 | 368,681 | 266,378 | 447,726 |
| Non-current assets | 228 | 115 | 10 | 27,640 | 22,390 | 318,476 | 307,011 | 295,814 |
| Current assets | 23,846 | 17,619 | 476,707 | 384,659 | 486,528 | 1,185,907 | 1,113,862 | 1,116,846 |
| Total assets | 24,074 | 17,734 | 476,717 | 412,299 | 508,918 | 1,504,383 | 1,420,873 | 1,412,660 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 271,908 | 769,079 | 427,164 |
| Social insurance contributions | - | - | - | - | - | - | - | 4,207 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -89.3% | +991.3% | +345.4% | +100.5% | -2.4% | +81.9% | -32.3% | +52.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -49.9% | 42.7% | 76.9% | 101.7% | 61.4% | 75.1% | 43.5% | 40.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | 112.1% | 155.4% | 77.0% | 99.5% | 53.5% | 59.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -104.1% | 6.0% | 65.3% | 37.2% | 28.4% | 56.5% | 45.7% | 27.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | 44.0% | 33.8% | 66.5% | 53.8% | 33.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 0.5 | 0.5 | 0.3 | 0.3 | 0.2 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 11,548 | 126,022 | 518,094 | 500,212 | 366,343 | 666,397 | 450,929 | 619,594 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ekstrameda - Social security debts
The company had no debts to Sodra
Ekstrameda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-07-28 | 2025-07-30 | 0.01 |
| 2025-06-19 | 2025-06-19 | 9.01 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ekstrameda, UAB (code 303054942) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €2.07M and net profit of €575.2K, with a profit margin of 27.9%. Revenue rose by 52.7% year on year and was 3.3% higher than two years earlier, showing a recovery from 2024, when turnover fell to €1.35M from €2.00M in 2023. Net profit also declined from €1.13M in 2023 to €618.3K in 2024 and €575.2K in 2025, indicating that profitability remained solid but at a lower level than in the earlier period. At year-end 2025, total assets stood at €1.41M, equity at €965.1K and liabilities at €447.7K. The equity ratio was 68.3% and debt-to-equity 0.46, suggesting a relatively strong balance sheet. Asset turnover was 1.46x. Based on staff data, revenue per employee was €688.4K and profit per employee €191.7K.